Nabla vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI clinical copilot. 85K+ clinicians, 130+ organizations. 20M patient interactions/year. Raised $70M Series C. Evolving to Adaptive Agentic Platform. Founded in Paris.
About
Nabla is a Paris-based clinical AI company founded in 2018 with a mission to reduce the documentation burden that is one of the primary drivers of clinician burnout across health systems globally. The company developed an AI clinical copilot that listens to patient-physician conversations and automatically generates structured clinical notes in the background, allowing clinicians to focus entirely on the patient rather than on documentation. Nabla's core technology applies large language models fine-tuned on medical language and SOAP note structure to produce accurate, editable documentation in real time.\n\nNabla's platform serves more than 85,000 clinicians across 130-plus organizations spanning hospitals, ambulatory practices, and digital health providers. It has facilitated over 20 million patient interactions per year, making it one of the highest-volume ambient AI documentation platforms in the market. The product supports more than 45 medical specialties, with specialty-specific note templates that reflect the distinct documentation requirements of fields ranging from psychiatry to orthopedics. Nabla is evolving its platform toward an Adaptive Agentic architecture, enabling the AI to take actions beyond note-taking — such as ordering follow-ups, drafting referrals, and surfacing clinical decision support.\n\nNabla raised a $70 million Series C to fund US expansion and platform development, following strong adoption in the European market. The company competes in the ambient clinical documentation space alongside Nuance DAX, Suki, and Abridge, but differentiates through its European regulatory expertise, multi-specialty coverage, and its strategic shift toward a full agentic clinical platform. With 20 million annual patient interactions and a clear product roadmap toward autonomous clinical workflow automation, Nabla is well positioned to grow into a broader clinical AI infrastructure role.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.